Last updated on September 2017

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer


Brief description of study

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Detailed Study Description

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

Eligible subjects were randomized 1:1 to sorafenib 800 mg daily or matching placebo. Progression was assessed every 8 weeks by modified RECIST criteria. Subjects had the option to unblind study treatment after progression and to receive open label sorafenib regardless of initial treatment assignment. Following discontinuation of study treatment, subjects were followed for survival every 3 months in long-term follow-up. Subjects who terminated study treatment (either double only or double blind and open label) for reasons other than death, lost to follow-up or consent withdrawn entered long-term follow up.

For Study Locations, Click Here

Clinical Study Identifier: TX152902

Contact Investigators or Research Sites near you

Start Over

Research Center

Additional Locations, XX Austria
  Connect »

Research Center

Additional Locations, XX Belgium
  Connect »

Research Center

Additional Locations, XX China
  Connect »

Research Center

Additional Locations, XX France
  Connect »

Research Center

Additional Locations, XX Germany
  Connect »

Research Center

Additional Locations, XX Italy
  Connect »

Research Center

Additional Locations, XX Japan
  Connect »

Research Center

Additional Locations, XX Poland
  Connect »

Research Center

Additional Locations, XX Russian Federation
  Connect »

Research Center

Additional Locations, XX Spain
  Connect »

Research Center

Additional Locations, XX Sweden
  Connect »

Research Center

Additional Locations, XX United Kingdom
  Connect »

Research Center

Additional Locations, CA USA
  Connect »

Research Center

Additional Locations, GA USA
  Connect »

Research Center

Additional Locations, MA USA
  Connect »

Research Center

Additional Locations, MO USA
  Connect »

Research Center

Additional Locations, NM USA
  Connect »

Research Center

Additional Locations, NY USA
  Connect »

Research Center

Additional Locations, PA USA
  Connect »

Research Center

Additional Locations, TN USA
  Connect »

Research Center

Additional Locations, TX USA
  Connect »

Research Center

Additional Locations, WA USA
  Connect »

Research Center

Additional Locations, XX Bulgaria
  Connect »

Research Center

Additional Locations, XX Republic of Korea
  Connect »

Research Center

Additional Locations, MI USA
  Connect »

Research Center

Additional Locations, OH USA
  Connect »

Research Center

Additional Locations, XX Denmark
  Connect »

Research Center

Additional Locations, XX Netherlands
  Connect »

Research Center

Additional Locations, XX Saudi Arabia
  Connect »

Research Center

Additional Locations, XX Slovakia
  Connect »

Research Center

Additional Locations, CT USA
  Connect »

Research Center

Additional Locations, OR USA
  Connect »

Research Center

Additional Locations, SC USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.